Drg1 was identified as a differentiation-related, putative metastatic suppressor gene in human colon and prostate cancer. Its expression is associated with resistance to irinotecan (CPT-11) therapy in preclinical colorectal cancer models both in vitro and in vivo. However, the functional significance of Drg1 in these processes is unknown. We have shown for the first time that Drg1 directly binds to the BH3-only proapoptotic protein Bim. Depletion of Drg1 by small interfering RNA induced up-regulation of Bim and its accumulation in the mitochondria, which correlated with loss of mitochondrial membrane potential and induction of apoptosis in cells exposed to SN-38. Further analyses revealed that Drg1 promotes degradation of Bim through the Cullin2/ElonginB-CIS ubiquitin-protein ligase complex. Conversely, in the absence of Drg1, Bim was stabilized and bound more abundantly to Hsp70. These results show that Drg1 renders cancer cells more resistant to chemotherapy through enhanced proteasome-mediated Bim degradation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2733857 | PMC |
| http://dx.doi.org/10.1158/0008-5472.CAN-08-3024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of fibrosis-associated lncRNAs in diabetic cardiomyopathy patients.
Endokrynol Pol
October 2024
The First Clinical Medical College, Jinan University, Guangzhou, China.
Introduction: Our study endeavours to ascertain the plasma-derived long noncoding ribonucleic acids (lncRNA) and messenger RNA (mRNA) expression profiles through gene microarray analysis, aiming to elucidate their potential biological roles in the development and progression of diabetic cardiomyopathy (DCM), particularly with respect to myocardial fibrosis.
Material And Methods: We conducted gene chip experiments to discern differences in lncRNA and mRNA expression profiles between diabetic cardiomyopathy and type 2 diabetes mellitus (T2DM). Differentially expressed mRNAs were subjected to functional enrichment analysis, thereby enabling the identification of key genes.
Anti-metastatic Effects of Bee Venom and Melittin in Breast Cancer Cells by Upregulation of BRMS1 and DRG1 Genes.
Chem Biol Drug Des
October 2024
Department of Molecular Biology and Genetics, Karadeniz Technical University, Trabzon, Turkey.
Apitherapy has started to gain tremendous recognition because of extraordinary pharmacological importance of honeybee-related ingredients and their derivatives. There has been a renewed interest in the bee venom-based therapies. Interdisciplinary researchers are studying the chemistry and translational value of venom for effective cancer treatment.
View Article and Find Full Text PDFRewiring protein binding specificity in paralogous DRG/DFRP complexes.
Structure
November 2024
Institute of Cancer and Genomics Sciences, University of Birmingham, B15 2TT Birmingham, UK. Electronic address:
Eukaryotes have two paralogous developmentally regulated GTP-binding (DRG) proteins: DRG1 and DRG2, both of which have a conserved binding partner called DRG family regulatory protein 1 and 2 (DFRP1 and DFRP2), respectively. DFRPs are important for the function of DRGs and interact with their respective DRG via a conserved region called the DFRP domain. Despite being highly similar, DRG1 and DRG2 have strict binding specificity for their respective DFRP.
View Article and Find Full Text PDFSubstrate selectivity and inhibition of the human lysyl hydroxylase JMJD7.
Protein Sci
October 2024
Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark.
Article Synopsis
- JMJD7 is a human enzyme that specifically modifies lysine residues in certain proteins, which is important for their function.
- Research indicates that JMJD7 has a limited range of substrates compared to other similar enzymes, but can efficiently use altered lysines for its reactions.
- The study identifies ways to inhibit JMJD7 by using variants of its substrates, which could aid in developing targeted therapies against diseases related to JMJD7 activity.
The long noncoding RNA CARDINAL attenuates cardiac hypertrophy by modulating protein translation.
J Clin Invest
May 2024
Department of Cardiology, Center for Translational Medicine, Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
One of the features of pathological cardiac hypertrophy is enhanced translation and protein synthesis. Translational inhibition has been shown to be an effective means of treating cardiac hypertrophy, although system-wide side effects are common. Regulators of translation, such as cardiac-specific long noncoding RNAs (lncRNAs), could provide new, more targeted therapeutic approaches to inhibit cardiac hypertrophy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!